Donaghue Woodman is the Head of Research and Development for CMG Global and Director for CannhealthMD, global pharmaceutical and educational based companies driving acceptance and change in the cannabis and psychedelic medicine space. She has more than 13 years of experience within the Pharmaceutical industry in the public and private sector. She is an MBA graduate, holds a degree in Biochemistry, Honours in Ethnopharmacology and has been awarded a scholarship in 2021 to undertake a Master’s in Psychology through Liverpool John Moores University in the UK. She is now heading the first women’s focused phase 2 psilocybin trial on the African continent. In this episode: A description of the psilocybin trials, including the theoretical basis, chosen target population, trial protocol, dosage, reliability and validity The interaction of oestrogen levels and psychedelics The significance of these trials in the South African mental health space Risks associated with commercialisation and capitalisation of psychedelics The importance of psychoeducation in the psychedelic space The importance of holistic psychedelic treatment models Readying your heart space for a psychedelic journey The potential of psychedelic medicine for individuals suffering from Schizophrenia Making psychedelic medicine accessible to all You can contact Donaghue at [email protected] or 0674006894 and you can find CannSun through their website https://cannsun.com/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related